RxDoctor Payments Data

Peter Wu, MD

Family Medicine · Sacramento, CANPI 1326143322

Payments from drug & device makers

$21,759in general payments, 2019–2025

Across 1,085 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Novo Nordisk$2K
  • GSK$1K
  • plus $11K from 40 others

What the payments were for

  • Food & beverage$21,46199%
  • Education$2981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,759 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$37,213
Medicare patients
104
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$95,534
EliquisApixaban40$43,838
FarxigaDapagliflozin Propanediol27$22,770
JanuviaSitagliptin Phosphate14$18,616
XareltoRivaroxaban18$17,515
MounjaroTirzepatide12$14,964
EntrestoSacubitril/Valsartan16$14,388
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,693
TradjentaLinagliptin14$9,613
BrilintaTicagrelor12$9,562
Fluticasone Propionate HfaFluticasone Propionate21$5,238
Colchicine19$3,551
Atorvastatin Calcium300$3,198
Icosapent Ethyl11$2,868
Omega-3 Acid Ethyl Esters30$2,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$1,171$105,14880 claims
PfizerEliquis$358$43,83840 claims
AstraZenecaFarxiga, Brilinta$2,258$32,33239 claims
MerckJanuvia$142$18,61614 claims
Johnson & JohnsonXarelto$1,970$17,51518 claims
Lilly USA, LLCMounjaro$1,605$14,96412 claims
NovartisEntresto$173$14,38816 claims
GSKTrelegy Ellipta$1,393$13,69322 claims
Scilex Pharmaceuticals Inc.Colchicine$100$3,55119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →